MiMedx Group (NASDAQ:MDXG) Stock Price Expected to Rise, Craig Hallum Analyst Says

MiMedx Group (NASDAQ:MDXG) had its price objective upped by stock analysts at Craig Hallum from $6.00 to $8.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s price objective points to a potential upside of 76.41% from the stock’s previous close.

A number of other brokerages have also recently commented on MDXG. Weiss Ratings restated a “sell (d)” rating on shares of MiMedx Group in a report on Thursday, August 13th. Wall Street Zen lowered shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Finally, Citizens Jmp cut their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and an average price target of $8.57.

MiMedx Group Trading Up 2.6%

NASDAQ MDXG traded up $0.12 on Thursday, reaching $4.54. The stock had a trading volume of 827,015 shares, compared to its average volume of 1,303,525. The firm has a market capitalization of $661.02 million, a price-to-earnings ratio of 113.40 and a beta of 1.45. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. MiMedx Group has a 12-month low of $3.03 and a 12-month high of $7.97. The stock has a fifty day moving average price of $4.15 and a two-hundred day moving average price of $4.10.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The business had revenue of $64.36 million during the quarter, compared to analyst estimates of $63.46 million. As a group, sell-side analysts forecast that MiMedx Group will post -0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MDXG. Kemnay Advisory Services Inc. purchased a new stake in shares of MiMedx Group in the 4th quarter valued at approximately $48,000. Sunbelt Securities Inc. purchased a new stake in shares of MiMedx Group during the 1st quarter worth $42,000. Jain Global LLC acquired a new position in shares of MiMedx Group during the fourth quarter worth $73,000. E Fund Management Co. Ltd. acquired a new position in shares of MiMedx Group during the second quarter worth $45,000. Finally, Virtu Financial LLC purchased a new position in MiMedx Group in the fourth quarter valued at $78,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.